Oxford BioDynamics
Plc
("OBD" or the
"Company" and, together
with its subsidiaries, the "Group")
Publication of 2024 Annual
Report
Oxford, UK - 5 March 2025 - Oxford BioDynamics Plc (AIM: OBD, the Company), a
precision clinical diagnostics company bringing specific and
sensitive tests to the practice of medicine based on its EpiSwitch®
3D genomics platform, announces that its annual report and accounts
for the year ended 30 September 2024 ("Annual Report") is available
in electronic form on its website
at www.oxfordbiodynamics.com/investors/financial-results. Hard
copies of the report (incorporating the Notice of Annual General
Meeting) will be posted to shareholders today.
As stated in the preliminary results
announcement on 28 February 2025, the Company's Annual General
Meeting will be held at 3140 Rowan Place, John Smith Drive, Oxford
Business Park South, Oxford, OX4 2WB, UK on 28 March 2025 at 10.00
am.
-Ends-
For further
details please contact:
|
Oxford
BioDynamics Plc
|
Tel: +44 (0)1865 518910
|
|
Iain Ross Executive Chairman
Paul Stockdale, CFO
|
|
|
Shore Capital
- Nominated Adviser and Broker
|
Tel: +44 (0)20 7408 4090
|
|
Advisory: Stephane Auton / Lucy
Bowden
Broking: Fiona Conroy
|
|
|
OAK Securities
- Joint Broker
|
Tel: +44 (0)20 3973 3678
|
|
Jerry Keen / Henry Clarke / Damion
Carruel
|
|
|
WG Partners -
Joint Broker
|
Tel: +44 (0)20 3705 9330
|
|
David Wilson / Claes Spång / Satheesh
Nadarajah / Erland Sternby
|
|
|
Camarco -
Financial PR
|
Tel: +44 (0)20 3757 4980
|
|
Marc Cohen / Tilly Butcher / Fergus
Young
|
OBDFinancial@camarco.co.uk
|
Notes to
Editors
About Oxford
BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is an
international biotechnology company, advancing personalized
healthcare by developing and commercializing precision clinical
diagnostic tests for life-changing diseases.
Currently OBD has two commercially
available products: the EpiSwitch®
PSE (EpiSwitch Prostate Screening
test) and EpiSwitch®
CiRT (Checkpoint Inhibitor Response Test)
blood tests. PSE boosts the predictive accuracy of a PSA test from
55% to 94% when testing the presence or absence of prostate
cancer. CiRT is a highly accurate (85%) predictive response
test to immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D
genomic biomarker platform, EpiSwitch® which enables
screening, evaluation, validation and monitoring of biomarkers to
diagnose patients or determine how individuals might respond to a
disease or treatment.
OBD's clinical smart tests have the potential to
be used across a broader range of indications, and new tests are
being developed in the areas of oncology, neurology, inflammation,
hepatology and animal health.
The Group's headquarters
and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along
with a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM
(LSE: OBD). For more information, please visit the Company's
website, www.oxfordbiodynamics.com,
X (@OxBioDynamics) or LinkedIn.
